For instance, tumor models responsive to CTLA-4 blockade commonly have a higher CD4+ T cell population [31], and the presence of pre-existing CD4+ T cells in the bloodstream has been shown to be associated with improved clinical outcomes in melanoma patients undergoing anti-CTLA-4 treatment [32]. The gene discussed is CD4; the disease is melanoma.